Xiang Lan1, Meng-Gang Liu1, Hong-Xu Chen1, Hong-Ming Liu1, Wei Zeng1, Dong Wei1, Ping Chen1. 1. Xiang Lan, Meng-Gang Liu, Hong-Xu Chen, Hong-Ming Liu, Wei Zeng, Dong Wei, Ping Chen, Department of Hepatobiliary Surgery, Daping Hospital, the Third Military Medical University, Chongqing 400042, China.
Abstract
AIM: To assess the advantages and disadvantages of immunosuppression monotherapy after transplantation and the impact of monotherapy on hepatitis C virus (HCV) recurrence. METHODS: Articles from Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials in The Cochrane Library, MEDLINE, EMBASE, and Science Citation Index Expanded, including non-English literature identified in these databases, were searched up to January 2013. We included randomized clinical trials comparing various immunosuppression monotherapy and prednisone-based immunosuppression combinations for liver transplantation. The modified Jadad scale score or the Oxford quality scoring system was used. Meta-analyses were performed with weighted random-effects models. RESULTS: A total of 14 randomized articles including 1814 patients were identified. Eight trials including 1214 patients compared tacrolimus monotherapy (n = 610) vs tacrolimus plus steroids or triple therapy regarding acute rejection and adverse events (n = 604). Five trials, including 285 patients, compared tacrolimus monotherapy (n = 143) vs tacrolimus plus steroids or triple therapy regarding hepatitis C recurrence (n = 142). Four trials including 273 patients compared cyclosporine monotherapy (n = 148) vs cyclosporine and steroids regarding acute rejection and adverse events (n = 125). Two trials including 170 patients compared mycophenolate mofetil monotherapy (n = 86) vs combinations regarding acute rejection (n = 84). There were no significant differences in the acute rejection rates between tacrolimus monotherapy (RR = 1.04, P = 0.620), and cyclosporine monotherapy (RR = 0.89, P = 0.770). Mycophenolate mofetil monotherapy had a significant increase in the acute rejection rate (RR = 4.50, P = 0.027). Tacrolimus monotherapy had no significant effects on the recurrence of hepatitis C (RR = 1.03, P = 0.752). More cytomegalovirus infection (RR = 0.48, P = 0.000) and drug-related diabetes mellitus (RR = 0.54, P = 0.000) were observed in the immunosuppression combination therapy groups. CONCLUSION: Tacrolimus and cyclosporine monotherapy may be as effective as immunosuppression combination therapy. Mycophenolate mofetil monotherapy was not considerable. Tacrolimus monotherapy does not increase recurrence of HCV.
AIM: To assess the advantages and disadvantages of immunosuppression monotherapy after transplantation and the impact of monotherapy on hepatitis C virus (HCV) recurrence. METHODS: Articles from Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials in The Cochrane Library, MEDLINE, EMBASE, and Science Citation Index Expanded, including non-English literature identified in these databases, were searched up to January 2013. We included randomized clinical trials comparing various immunosuppression monotherapy and prednisone-based immunosuppression combinations for liver transplantation. The modified Jadad scale score or the Oxford quality scoring system was used. Meta-analyses were performed with weighted random-effects models. RESULTS: A total of 14 randomized articles including 1814 patients were identified. Eight trials including 1214 patients compared tacrolimus monotherapy (n = 610) vs tacrolimus plus steroids or triple therapy regarding acute rejection and adverse events (n = 604). Five trials, including 285 patients, compared tacrolimus monotherapy (n = 143) vs tacrolimus plus steroids or triple therapy regarding hepatitis C recurrence (n = 142). Four trials including 273 patients compared cyclosporine monotherapy (n = 148) vs cyclosporine and steroids regarding acute rejection and adverse events (n = 125). Two trials including 170 patients compared mycophenolate mofetil monotherapy (n = 86) vs combinations regarding acute rejection (n = 84). There were no significant differences in the acute rejection rates between tacrolimus monotherapy (RR = 1.04, P = 0.620), and cyclosporine monotherapy (RR = 0.89, P = 0.770). Mycophenolate mofetil monotherapy had a significant increase in the acute rejection rate (RR = 4.50, P = 0.027). Tacrolimus monotherapy had no significant effects on the recurrence of hepatitis C (RR = 1.03, P = 0.752). More cytomegalovirus infection (RR = 0.48, P = 0.000) and drug-related diabetes mellitus (RR = 0.54, P = 0.000) were observed in the immunosuppression combination therapy groups. CONCLUSION:Tacrolimus and cyclosporine monotherapy may be as effective as immunosuppression combination therapy. Mycophenolate mofetil monotherapy was not considerable. Tacrolimus monotherapy does not increase recurrence of HCV.
Authors: H J Schlitt; A Barkmann; K H Böker; H H Schmidt; N Emmanouilidis; J Rosenau; M J Bahr; G Tusch; M P Manns; B Nashan; J Klempnauer Journal: Lancet Date: 2001-02-24 Impact factor: 79.321
Authors: F Romani; L S Belli; L De Carlis; G F Rondinara; A Alberti; C V Sansalone; G Bellati; C Zavaglia; E Fesce; G Ideo Journal: Transplant Proc Date: 1994-10 Impact factor: 1.066
Authors: R T Padbury; B K Gunson; B Dousset; S G Hubscher; J A Buckels; J M Neuberger; E Elias; P McMaster Journal: Transplantation Date: 1993-04 Impact factor: 4.939
Authors: L Ghio; A Tarantino; A Edefonti; A Mocciaro; M Giani; L Guerra; L Berardinelli; A Vegeto Journal: Transplantation Date: 1992-11 Impact factor: 4.939
Authors: S P Dunn; K Falkenstein; J P Lawrence; R Meyers; C D Vinocur; D F Billmire; W H Weintraub Journal: Transplantation Date: 1994-02-27 Impact factor: 4.939
Authors: Manuel Rodríguez-Perálvarez; Marta Guerrero-Misas; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy Journal: Cochrane Database Syst Rev Date: 2017-03-31
Authors: Sammy Saab; Justin Rheem; Melissa Jimenez; Sherona Bau; Gina Choi; Francisco Durazo; Mohammed El Kabany; Steven Han; Alexander Farid; Naadir Jamal; Jonathan Grotts; David Elashoff; Ronald W Busuttil Journal: J Clin Transl Hepatol Date: 2016-03-15